RedHill Biopharma Says FDA Granted Orphan-Drug Designation To Opaganib For Treatment Of Neuroblastoma, A Type Of Childhood Cancer
Portfolio Pulse from Benzinga Newsdesk
RedHill Biopharma's drug Opaganib has received Orphan-Drug Designation from the FDA for treating neuroblastoma, a type of childhood cancer. This designation could lead to a seven-year marketing exclusivity and other benefits if approved.
August 26, 2024 | 11:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RedHill Biopharma's Opaganib has been granted Orphan-Drug Designation by the FDA for neuroblastoma treatment, potentially leading to a seven-year marketing exclusivity and other benefits if approved.
The FDA's Orphan-Drug Designation for Opaganib in treating neuroblastoma is significant for RedHill Biopharma as it could lead to a seven-year marketing exclusivity, accelerated development, and potential financial benefits. This news is likely to positively impact RDHL's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100